CN103710367B - 一种重组人激肽释放酶1及其编码基因和制备方法 - Google Patents
一种重组人激肽释放酶1及其编码基因和制备方法 Download PDFInfo
- Publication number
- CN103710367B CN103710367B CN201310718972.XA CN201310718972A CN103710367B CN 103710367 B CN103710367 B CN 103710367B CN 201310718972 A CN201310718972 A CN 201310718972A CN 103710367 B CN103710367 B CN 103710367B
- Authority
- CN
- China
- Prior art keywords
- buffer
- human kallikrein
- recombined human
- kallikrein
- coli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 title claims abstract description 145
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title description 8
- 230000014509 gene expression Effects 0.000 claims abstract description 61
- 241000282414 Homo sapiens Species 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 26
- 210000003000 inclusion body Anatomy 0.000 claims abstract description 25
- 230000009465 prokaryotic expression Effects 0.000 claims abstract description 5
- 241000588724 Escherichia coli Species 0.000 claims description 52
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 25
- 238000004153 renaturation Methods 0.000 claims description 24
- 238000001556 precipitation Methods 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 239000000872 buffer Substances 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 15
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 15
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 13
- 101710176219 Kallikrein-1 Proteins 0.000 claims description 12
- 102000057032 Tissue Kallikreins Human genes 0.000 claims description 12
- 239000007853 buffer solution Substances 0.000 claims description 12
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 239000013613 expression plasmid Substances 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 235000015097 nutrients Nutrition 0.000 claims description 7
- 230000000392 somatic effect Effects 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 6
- 238000004925 denaturation Methods 0.000 claims description 6
- 230000036425 denaturation Effects 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 5
- 229960000723 ampicillin Drugs 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000012139 lysis buffer Substances 0.000 claims description 4
- 239000012460 protein solution Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 3
- 235000010335 lysozyme Nutrition 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 102000016943 Muramidase Human genes 0.000 claims description 2
- 108010014251 Muramidase Proteins 0.000 claims description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 2
- -1 and 10mmol/L DTT Substances 0.000 claims description 2
- 229960000274 lysozyme Drugs 0.000 claims description 2
- 239000004325 lysozyme Substances 0.000 claims description 2
- 238000005374 membrane filtration Methods 0.000 claims description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 5
- 239000012153 distilled water Substances 0.000 claims 5
- 239000011159 matrix material Substances 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 239000004202 carbamide Substances 0.000 claims 2
- 206010010254 Concussion Diseases 0.000 claims 1
- 108010053070 Glutathione Disulfide Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- 229920004890 Triton X-100 Polymers 0.000 claims 1
- 239000013504 Triton X-100 Substances 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 230000009514 concussion Effects 0.000 claims 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 108020004705 Codon Proteins 0.000 abstract description 36
- 238000000746 purification Methods 0.000 abstract description 22
- 102000001399 Kallikrein Human genes 0.000 abstract description 13
- 108060005987 Kallikrein Proteins 0.000 abstract description 13
- 102100038297 Kallikrein-1 Human genes 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 241000588722 Escherichia Species 0.000 abstract description 4
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 2
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009182 swimming Effects 0.000 description 37
- 230000006698 induction Effects 0.000 description 25
- 239000000523 sample Substances 0.000 description 22
- 239000006166 lysate Substances 0.000 description 17
- 239000002585 base Substances 0.000 description 16
- 238000001514 detection method Methods 0.000 description 16
- 150000001413 amino acids Chemical group 0.000 description 14
- 238000005457 optimization Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 108010025252 Kassinin Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000000703 high-speed centrifugation Methods 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 8
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 7
- 210000002429 large intestine Anatomy 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102100026678 Carboxypeptidase N catalytic chain Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 101000910843 Homo sapiens Carboxypeptidase N catalytic chain Proteins 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 2
- 108091062157 Cis-regulatory element Proteins 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 2
- 102000002261 High-Molecular-Weight Kininogen Human genes 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010093008 Kinins Proteins 0.000 description 2
- 102000002397 Kinins Human genes 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 101150100366 end gene Proteins 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 210000002706 plastid Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940047431 recombinate Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 240000005708 Eugenia stipitata Species 0.000 description 1
- 235000006149 Eugenia stipitata Nutrition 0.000 description 1
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010058188 Low-Molecular-Weight Kininogen Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101000605527 Rattus norvegicus Kallikrein-1 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- SPTYHKZRPFATHJ-HYZXJONISA-N dT6 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 SPTYHKZRPFATHJ-HYZXJONISA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 102000043557 human IFNG Human genes 0.000 description 1
- 108010002492 human interferon alfa-1b Proteins 0.000 description 1
- 102000000707 human interferon alfa-1b Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
顺式作用元件 | 优化前 | 优化后 |
E.coli_RBS(AGGAGG) | 0 | 0 |
PolyT(TTTTTT) | 0 | 0 |
PolyA(AAAAAAA) | 0 | 0 |
Chi_sites(GCTGGTGG) | 0 | 0 |
T7Cis(ATCTGTT) | 0 | 0 |
SD_like(GGRGGT) | 1 | 0 |
分组 | 诱导剂IPTG浓度(mmol/L) | 诱导时间T(h) |
1 | 0.5 | 2 |
2 | 0.5 | 3 |
3 | 0.5 | 4 |
4 | 0.5 | 5 |
5 | 0.8 | 2 |
6 | 0.8 | 3 |
7 | 0.8 | 4 |
8 | 0.8 | 5 |
9 | 1.2 | 2 |
10 | 1.2 | 3 |
11 | 1.2 | 4 |
12 | 1.2 | 5 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310718972.XA CN103710367B (zh) | 2013-12-23 | 2013-12-23 | 一种重组人激肽释放酶1及其编码基因和制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310718972.XA CN103710367B (zh) | 2013-12-23 | 2013-12-23 | 一种重组人激肽释放酶1及其编码基因和制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103710367A CN103710367A (zh) | 2014-04-09 |
CN103710367B true CN103710367B (zh) | 2016-08-24 |
Family
ID=50403723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310718972.XA Active CN103710367B (zh) | 2013-12-23 | 2013-12-23 | 一种重组人激肽释放酶1及其编码基因和制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103710367B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104558100A (zh) * | 2015-02-04 | 2015-04-29 | 吉林农业大学 | 包涵体的预处理方法 |
CN106520796A (zh) * | 2016-11-04 | 2017-03-22 | 江苏众红生物工程创药研究院有限公司 | 一种重组n‑糖酰胺酶f及其编码基因和应用 |
CN108822202B (zh) * | 2018-02-07 | 2021-11-30 | 电子科技大学 | 一种草鱼白细胞介素21重组蛋白及其制备方法 |
CN109721651B (zh) * | 2018-12-28 | 2020-12-29 | 江苏众红生物工程创药研究院有限公司 | 一种视黄醇结合蛋白检测试剂盒及其临床应用 |
CN113073092A (zh) * | 2021-04-15 | 2021-07-06 | 宁波瑞林生物科技有限公司 | 重组人组织型激肽释放酶及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1384199A (zh) * | 2001-02-20 | 2002-12-11 | 深圳市人民医院 | 一种表达人胰腺组织激肽释放酶基因的重组表达载体及重组人胰腺组织激肽释放酶的制备 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01300892A (ja) * | 1988-05-27 | 1989-12-05 | Kyoichi Kobashi | ウレタナーゼおよびその製造法 |
-
2013
- 2013-12-23 CN CN201310718972.XA patent/CN103710367B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1384199A (zh) * | 2001-02-20 | 2002-12-11 | 深圳市人民医院 | 一种表达人胰腺组织激肽释放酶基因的重组表达载体及重组人胰腺组织激肽释放酶的制备 |
Non-Patent Citations (7)
Title |
---|
Cloning and expression of human salivary-gland kallikrein in Escherichia coli;Axel ANGERMANN et al;《Biochem. J.》;19891231;第262卷;787-793 * |
kallikrein [Homo sapiens];Evans,B.A. et al;《GenBank: AAA59455.1》;19950106;全文 * |
Periplasmic production of human pancreatic prokallikrein in Escherichia coli;Tatsurou Shibui et al;《Appl Microbiol Biotechnol》;19891231;第31卷;253-258 * |
人组织激肽释放酶成熟蛋白在大肠杆菌中的高效表达;李体远 等;《中国生物化学与分子生物学报》;20030630;312-316 * |
人胰腺激肽释放酶cDNA的克隆_序列分析和原核表达;施伟庆 等;《农业生物技术学报》;20031231;169-172 * |
大肠杆菌表达重组人胰激肽原酶;侯乐锋;《中国优秀硕士学位论文全文数据库》;20120515;摘要、第2.4.2节、第4.5.4节 * |
重组人胰激肽原酶发酵及复性研究;郭平川;《中国优秀硕士学位论文全文数据库》;20121115;第三章 * |
Also Published As
Publication number | Publication date |
---|---|
CN103710367A (zh) | 2014-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103710367B (zh) | 一种重组人激肽释放酶1及其编码基因和制备方法 | |
CN104402975B (zh) | 抗衰老短肽及其制备方法 | |
CN102978231A (zh) | 一种重组人表皮生长因子工程菌的构建和筛选方法 | |
CN101845439B (zh) | 家蚕培养细胞表达抗菌肽Cecropin B的方法 | |
CN103193887B (zh) | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 | |
CN110628738B (zh) | 提高葡萄糖氧化酶活性的方法、突变体及其应用 | |
CN106939315B (zh) | 一种草酸脱羧酶的制备方法及应用 | |
CN102994601A (zh) | 一种利用海洋胶原蛋白酶mcp-01制备胶原蛋白小肽的方法 | |
CN106929496A (zh) | 一种药用级重组人激肽原酶产业化生产方法 | |
CN103265637B (zh) | 一种重组猪白细胞介素4-Fc融合蛋白及其编码基因和表达方法 | |
CN103360497A (zh) | 一种新型抗肿瘤融合蛋白疫苗及其制备方法和应用 | |
CN110079539B (zh) | 前列腺酸性磷酸酶/粒-巨噬细胞集落刺激因子制备方法 | |
CN103012578B (zh) | 一种重组猪白细胞介素2及其编码基因和表达方法 | |
CN108239632A (zh) | 一种热稳定性得到改善的d-阿洛酮糖-3-差向异构酶的突变体及其应用 | |
CN103012577A (zh) | 一种重组猪白细胞介素4及其编码基因和表达方法 | |
CN103397038B (zh) | 一种人白细胞介素-38的生产方法 | |
CN100491399C (zh) | p53蛋白的表位与丝状噬菌体基因8蛋白的杂合蛋白及其应用 | |
CN102898514A (zh) | 重组人神经生长因子缺失突变体及其制备方法和用途 | |
CN102898512B (zh) | 一种重组菌丝霉素及其制备方法和用途 | |
CN103031295B (zh) | 冬虫夏草胞苷脱氨酶、编码基因及其应用 | |
CN103509100B (zh) | 一种白细胞介素‑1受体拮抗剂突变体 | |
CN101967468A (zh) | 一种重组人胰激肽原酶 | |
CN108218996A (zh) | 重组蛋白及其纯化制备方法 | |
CN101089181A (zh) | 重组人白细胞介素-4的生产方法 | |
CN111732667B (zh) | 小反刍兽疫病毒基因工程亚单位疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 213125 Jiangsu city of Changzhou Province Cloud River New District No. 518 Changzhou Qianhong biochemical pharmaceutical biological all red Patentee after: ZonHon Biopharma Institute Inc. Patentee after: Changzhou Gensun Institute of Biomedicine Co., Ltd. Address before: 213022 the Yellow River Middle Road, Xinbei District, Jiangsu, China, No. 132, No. Patentee before: ZonHon Biopharma Institute Inc. Patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. |
|
CP02 | Change in the address of a patent holder |
Address after: 213125, Yunhe Road, Xinbei District, Jiangsu, Changzhou, 518 Co-patentee after: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee after: ZonHon Biopharma Institute Inc. Address before: 213125 Jiangsu city of Changzhou Province Cloud River New District No. 518 Changzhou Qianhong biochemical pharmaceutical biological all red Co-patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
CP02 | Change in the address of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee after: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Patentee after: ZonHon Biopharma Institute Inc. Address before: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190517 Address after: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Patentee after: ZonHon Biopharma Institute Inc. Address before: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee before: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
TR01 | Transfer of patent right |